The global impact of the ongoing U.S.–Iran conflict is now reaching everyday consumer goods, with the world’s largest condom manufacturer, Karex, announcing plans to raise prices by up to 30%. The move highlights how geopolitical tensions are disrupting supply chains and driving up costs across industries.
Karex, which produces billions of condoms annually and supplies major global brands, says the price hikes are a direct result of rising production and logistics expenses linked to the conflict. The war has significantly disrupted the flow of key raw materials—many of which are derived from petrochemicals—such as synthetic rubber, nitrile, lubricants, and packaging materials. These inputs have seen cost increases of as much as 25–30% since the conflict began.
One of the biggest challenges has been the disruption of shipping routes, particularly around the Strait of Hormuz, a critical artery for global oil and chemical supplies. Delays have doubled delivery times to major markets like the United States and Europe, further increasing operational costs and tightening supply.
At the same time, global demand for condoms has surged, with some reports indicating a rise of nearly 30%. Economic uncertainty and shifting social behavior during periods of instability often lead to increased demand for contraceptives, putting additional pressure on already strained supply chains.
The broader economic backdrop is also contributing to the price surge. The Iran war has triggered volatility in global energy markets, pushing oil prices higher and increasing transportation and manufacturing costs across sectors. As a result, Karex and other manufacturers are being forced to pass these costs on to consumers.
This development underscores how interconnected global markets have become. A regional conflict is no longer confined to political or military consequences—it can quickly translate into higher prices for everyday essentials worldwide.
If disruptions continue, experts warn that further price increases and supply shortages could follow, raising concerns not only for consumers but also for public health programs that rely on affordable access to contraceptives.
